MEDFORD, N.Y. , March 14, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announces that Lawrence Siebert , Chief Executive Officer, will present at the ROTH Capital Partners 25th Annual Growth Stock Conference to
Fourth Quarter Product Sales Up 25%, Full-Year Product Sales Up 40% Conference Call Begins at 5:00 p.m. Eastern Time Today MEDFORD, N.Y., March 7, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported
MEDFORD, N.Y. , Jan. 29, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announces that its U.S. Department of Agriculture (USDA)-licensed products, CervidTB STAT-PAK ® and DPP ® VetTB, have been approved as
MEDFORD, N.Y. , Jan. 4, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests, today announced that Lawrence Siebert , Chief Executive Officer of Chembio, will present a corporate overview at the Sidoti & Company LLC's ( www.sidoti.com
MEDFORD, N.Y. , Dec. 21, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI),a leader in point-of-care diagnostic tests for infectious diseases, announces receipt of approval from the U.S. Food and Drug Administration (FDA) to market the Company's Dual Path Platform ® (DPP ® ) HIV 1/2
Company Highlights the Clinical Utility of Its Dual Path Platform Rapid, Point-of-Care Tests in HIV and Related Infectious Diseases including Syphilis and Hepatitis-C
MEDFORD, N.Y. , Dec. 4, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests, today announced that Lawrence Siebert , Chief Executive Officer of Chembio, will present a corporate overview at the LD Micro V: Main Event Conference on
Print Page